Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163332
Status:
COMPLETED
Last Update Posted:
2016-12-06
First Post:
2005-09-12
Brief Title:
Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma 18 to 65 y BY9010M1-129
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Comparison of Inhaled Ciclesonide 160 mcg bid or 320 mcg bid and Fluticasone Propionate 250 mcg bid or 500 mcg bid in Pretreated Patients With Mild to Moderate Asthma
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to investigate the effect of ciclesonide versus fluticasone propionate versus placebo on airway hyperresponsiveness and on the hypothalamic-pituitary-adrenal axis HPA axis Treatment medication will be administered as follows ciclesonide or fluticasone propionate will be inhaled twice daily using one of the two dose levels The study duration consists of a baseline period 4 to 6 weeks five treatment periods 9 days each and a washout period between treatments 4 to 12 weeks The study will provide further data on safety and tolerability of ciclesonide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None